News
Approximately two-thirds of patients responded to teduglutide, which is sold under the brand name Gattex as a treatment for ...
Runners, cyclists and other fitness enthusiasts say weight-loss drugs give them a performance edge, despite potential risks.
The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...
This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...
Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...
The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results